A New Probiotic Blend Facilitates Resolution of Inflammation in a Crohn’s Disease Mouse Model by Promoting Apoptosis in Mucosal Innate Immune Cells

The interaction between gut-residing microorganisms plays a critical role in the pathogenesis of Crohn’s disease (CD), where microbiome dysregulation can alter immune responses leading to unresolved local inflammation. The aim of this study is to analyze the immunomodulatory properties of our recently developed probiotic+amylase blend in the SAMP1/YitFc (SAMP) mouse model of CD-like ileitis. Four groups of SAMP mice were gavaged for 56 days with: 1) probiotic strains + amylase (concentration: 0.25 mg/100 uL PBS); 2) only probiotics; 3) only amylase; PBS (vehicle-treated controls). Ilea were collected for GeoMx Digital Spatial Profiler (DSP) analysis and histological evaluation. Histology assessment for inflammation indicated a significantly reduced level of ileitis in mice administered probiotics+amylase blend. DSP analysis showed decreased abundance of neutrophils and increased abundance of dendritic cells, innate lymphoid cells and macrophages, with a significant enrichment of five intracellular pathways related to apoptosis, in probiotics+amylase treated mice. Increased apoptosis occurrence was confirmed by TUNEL assay. Our data demonstrate a beneficial role of the probiotic and amylase blend, highlighting an increased apoptosis of innate immunity-associated cell subsets, thus promoting the resolution of inflammation. Hence, we suggest that our recently developed probiotic blend may be a therapeutic tool to manage CD and therefore could be a candidate compound to be tested in clinical trials.